23andMe Holding Co. (NASDAQ:ME) Short Interest Update

23andMe Holding Co. (NASDAQ:ME) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 950,200 shares, a decline of 16.6% from the November 15th total of 1,140,000 shares. Based on an average trading volume of 325,600 shares, the days-to-cover ratio is currently 2.9 days. Approximately 5.9% of the company’s shares are sold short.

23andMe Trading Up 0.6 %

ME stock opened at $3.35 on Friday. The firm has a market cap of $87.50 million, a PE ratio of -0.13 and a beta of 1.15. The stock has a 50-day moving average price of $4.33 and a 200-day moving average price of $6.58. 23andMe has a 1-year low of $2.65 and a 1-year high of $20.40.

23andMe (NASDAQ:ME) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($2.32) earnings per share for the quarter. The company had revenue of $44.07 million during the quarter, compared to the consensus estimate of $50.30 million. 23andMe had a negative net margin of 318.39% and a negative return on equity of 129.98%.

Institutional Trading of 23andMe

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its stake in 23andMe by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock valued at $1,476,000 after purchasing an additional 28,252 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of 23andMe during the third quarter valued at approximately $805,000. FMR LLC grew its holdings in 23andMe by 24.0% during the third quarter. FMR LLC now owns 993,848 shares of the company’s stock worth $345,000 after buying an additional 192,099 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in 23andMe in the 2nd quarter valued at $203,000. Finally, AQR Capital Management LLC lifted its stake in 23andMe by 145.8% during the 2nd quarter. AQR Capital Management LLC now owns 444,222 shares of the company’s stock valued at $174,000 after acquiring an additional 263,468 shares in the last quarter. Institutional investors and hedge funds own 36.10% of the company’s stock.

About 23andMe

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.